ZEISS MEL 90 Excimer Laser Gains FDA Approval: A Revolution in Refractive Surgery
In a significant advancement for refractive surgery, ZEISS Medical Technology has announced that its MEL® 90 excimer laser has received approval from the U.S. Food and Drug Administration (FDA). This vital achievement permits the use of this cutting-edge excimer laser technology for the treatment of three major eye conditions—myopia, hyperopia, and mixed astigmatism—reflecting ZEISS's ongoing commitment to enhancing patient care in the vision correction field.
The MEL 90 excimer laser is designed to be fully integrated into the Corneal Refractive Workflow, offering eye surgeons in the U.S. a streamlined and efficient surgical experience. As a complement to the sophisticated VISUMAX® 800 with SMILE® pro, this integration is set to bolster refractive practices, enabling surgeons to attract a broader patient base while delivering clinical excellence.
Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology, highlighted the global trend towards laser vision correction and the positive impact it has on patient quality of life. He stated, "With the integration of the ZEISS MEL 90, surgeons can confidently care for their patients with boosted workflow efficiency and enhanced surgical outcomes." This sentiment is echoed by Andrew Chang, Head of Global Sales for ZEISS Medical Technology, who noted that the MEL 90 is a testament to ZEISS's leadership in the laser vision correction market, bringing advanced technology to U.S. surgeons and their patients.
Dr. John Doane, a refractive surgeon at Discover Vision Centers in Kansas City, MO, emphasized the importance of this FDA approval, describing it as a "game changer" for refractive surgery in the U.S. He remarked that the MEL 90, characterized by its innovative Triple-A ablation algorithm and swift ablation speed, sets new standards for precision, safety, and efficiency in refractive procedures.
The unique Triple-A (Advanced Ablation Algorithm) allows for a significantly simplified treatment planning process while ensuring reliable and tissue-conserving results. The system’s preinstalled features provide optimal support for surgeons aiming to achieve outstanding treatment outcomes across varied levels of ametropia and astigmatism, whether standard, higher, or lower.
When executing LASIK for myopia, the ZEISS MEL 90 excels, demonstrating an impressive ablation capability of 1 diopter in just 1.3 seconds at 500 Hz, significantly streamlining surgical procedures. Moreover, the inclusion of an active eye tracker enhances treatment safety, ensuring excellent response times for stable outcomes.
Ease of use is another advantage of the ZEISS MEL 90, which has been meticulously designed to facilitate interaction among the surgical team, including the surgeon and support staff. Configurable to suit specific needs, the system features an intuitive graphic user interface and ergonomic functionalities that accommodate a comfortable working posture during operations.
Additionally, surgeons will appreciate the MEL 90's advanced connectivity options, including an HD video port and a network printer connection, further promoting efficiency and seamless workflow integration.
As ZEISS continues to innovate within the refractive surgery landscape, the introduction of the MEL 90 excimer laser not only expands their offerings on the U.S. market but also underscores their dedication to improving clinical outcomes and elevating patient satisfaction. With comprehensive onboarding, training, and service support, ZEISS actively empowers refractive clinics in their pursuit of excellence.
The ZEISS MEL 90 is now available across the United States, paving the way for enhanced patient care through superior laser technology. To learn more about this state-of-the-art system and its transformative potential within refractive surgery, please visit ZEISS Medical Technology.
The MEL 90 excimer laser is designed to be fully integrated into the Corneal Refractive Workflow, offering eye surgeons in the U.S. a streamlined and efficient surgical experience. As a complement to the sophisticated VISUMAX® 800 with SMILE® pro, this integration is set to bolster refractive practices, enabling surgeons to attract a broader patient base while delivering clinical excellence.
Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology, highlighted the global trend towards laser vision correction and the positive impact it has on patient quality of life. He stated, "With the integration of the ZEISS MEL 90, surgeons can confidently care for their patients with boosted workflow efficiency and enhanced surgical outcomes." This sentiment is echoed by Andrew Chang, Head of Global Sales for ZEISS Medical Technology, who noted that the MEL 90 is a testament to ZEISS's leadership in the laser vision correction market, bringing advanced technology to U.S. surgeons and their patients.
Dr. John Doane, a refractive surgeon at Discover Vision Centers in Kansas City, MO, emphasized the importance of this FDA approval, describing it as a "game changer" for refractive surgery in the U.S. He remarked that the MEL 90, characterized by its innovative Triple-A ablation algorithm and swift ablation speed, sets new standards for precision, safety, and efficiency in refractive procedures.
The unique Triple-A (Advanced Ablation Algorithm) allows for a significantly simplified treatment planning process while ensuring reliable and tissue-conserving results. The system’s preinstalled features provide optimal support for surgeons aiming to achieve outstanding treatment outcomes across varied levels of ametropia and astigmatism, whether standard, higher, or lower.
When executing LASIK for myopia, the ZEISS MEL 90 excels, demonstrating an impressive ablation capability of 1 diopter in just 1.3 seconds at 500 Hz, significantly streamlining surgical procedures. Moreover, the inclusion of an active eye tracker enhances treatment safety, ensuring excellent response times for stable outcomes.
Ease of use is another advantage of the ZEISS MEL 90, which has been meticulously designed to facilitate interaction among the surgical team, including the surgeon and support staff. Configurable to suit specific needs, the system features an intuitive graphic user interface and ergonomic functionalities that accommodate a comfortable working posture during operations.
Additionally, surgeons will appreciate the MEL 90's advanced connectivity options, including an HD video port and a network printer connection, further promoting efficiency and seamless workflow integration.
As ZEISS continues to innovate within the refractive surgery landscape, the introduction of the MEL 90 excimer laser not only expands their offerings on the U.S. market but also underscores their dedication to improving clinical outcomes and elevating patient satisfaction. With comprehensive onboarding, training, and service support, ZEISS actively empowers refractive clinics in their pursuit of excellence.
The ZEISS MEL 90 is now available across the United States, paving the way for enhanced patient care through superior laser technology. To learn more about this state-of-the-art system and its transformative potential within refractive surgery, please visit ZEISS Medical Technology.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.